腦梗死患者應(yīng)用依達(dá)拉奉聯(lián)合神經(jīng)節(jié)苷脂對臨床效果及神經(jīng)功能缺損癥狀的影響

[摘要] 目的 探究腦梗死患者應(yīng)用依達(dá)拉奉聯(lián)合神經(jīng)節(jié)苷脂對臨床效果及神經(jīng)功能缺損癥狀的影響。方法 整群選取該院2014年4月—2016年7月收治的106例腦梗死患者臨床資料進行分析，按照治療方式的不同分為對照組（53例）與研究組（53例），對照組予以依拉達(dá)奉進行治療，研究組于對照組基礎(chǔ)予以神經(jīng)節(jié)苷脂進行聯(lián)合治療，觀察兩組神經(jīng)功能缺損情況、血液流變學(xué)指標(biāo)以及日常生活能力變化情況。結(jié)果 研究組與對照組在治療前NIHSS評分分別為（22.69±5.57）分和（22.78±5.49）分，二者比較差異無統(tǒng)計學(xué)意義（P>0.05），治療之后1周與2周NIHSS評分研究組（14.91±6.19）分、（7.58±6.18）分較對照組（18.63±6.30）分、（14.33±6.18）分低，比較差異有統(tǒng)計學(xué)意義（P<0.05），治療后研究組血液流變學(xué)指標(biāo)中纖維蛋白原（3.19±0.17）g/L、血漿黏度（1.62±0.20）mPa.s、I/S全血黏度切變率（18.03±2.04）mPa.s改善情況顯著較對照組（3.59±0.23）g/L、（1.86±0.23）mPa.s、（21.86±2.13）mPa.s優(yōu)，比較差異有統(tǒng)計學(xué)意義（P<0.05），治療前ADL評分研究組（23.17±4.33）分與對照組（23.08±4.36）分，比較差異無統(tǒng)計學(xué)意義（P>0.05），治療1周、2周后研究組評分為（41.48±4.72）分、（63.45±9.34）分與對照組（35.91±4.59）分、（54.47±9.05）分相比顯著較高，差異有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 腦梗死采取神經(jīng)節(jié)苷脂與依達(dá)拉奉進行聯(lián)合治療能夠有效改善患者神經(jīng)功能狀態(tài)，提高臨床療效并改善其日常生活能力，且藥物不良反應(yīng)較少，具有臨床推廣及應(yīng)用價值。

[關(guān)鍵詞] 腦梗死；神經(jīng)節(jié)苷脂；依達(dá)拉奉

[中圖分類號] R5 [文獻(xiàn)標(biāo)識碼] A [文章編號] 1674-0742（2016）12（c）-0104-03

[Abstract] Objective To study the effect of edaravone combined with ganglioside on clinical outcome and neurological deficits in patients with cerebral infarction. Methods Group selection from April 2014 to July 2016 in our hospital， 106 patients with cerebral infarction were divided into control group（53 cases） and study group（53 cases） according to the different treatment methods. The control group was treated by ILADA，and the study group given gangliosides for joint treatmentbased onthe control group.The neurological deficits， hemorheological indexes and daily living ability of the two groups were observed.Results The NIHSS scores of the study group and the control group were （22.69 ± 5.57）points and （22.78 ± 5.49） points respectively. There was no significant difference between the study group and the control group（P>0.05）. After 1 and 2 weeks of treatment，（14.91±6.19）points，（7.58±6.18）points of study group was lower than the control group（18.63±6.30）points， （14.33±6.18）points， the difference was statistically significant（P<0.05）， After treatment，the hemorheological indicators of fibrinogen（3.19±0.17）g/L， plasma viscosity（1.62±0.20）mPa.s and I/S shear rate of whole blood viscosity （18.03 ± 2.04） mPa.s of study group improved significantly compared with the control group（3.59±0.23）g/L、（1.86±0.23）mPa.s、（21.86±2.13）mPa.s， the difference was statistically significant（P<0.05）.There was no significant difference between ADL score （23.17 ± 4.33）points and control group（23.08 ± 4.36）points before treatment（P> 0.05）.After 1 and 2 weeks of treatment， the score of the study group was （41.48±4.72）points， （63.45±9.34） points was significantly higher than that of the control group（35.91±4.59）points and （54.47±9.05）points（P<0.05）.Conclusion Combination of ganglioside and edaravone could improve the neurological function， improve the clinical curative effect and improve the daily living ability of patients with cerebral infarction. Adverse drug reactions are less，which have clinical application and value.

[Key words] Cerebral infarction； Gangliosides； Edaravone

腦梗死發(fā)生主要是因腦組織出現(xiàn)局部血液循環(huán)障礙，導(dǎo)致缺氧缺血以及腦組織軟化壞死，其致殘率較高，嚴(yán)重威脅患者生命健康[1]。因此，予以早期診斷然后制定相應(yīng)治療方案進行規(guī)范化治療，可有效提升治療效果并改善神經(jīng)系統(tǒng)功能。……